Skip to content

Study · Not a test of the peptide alone · 1990

2 results

Naloxone interaction with pituitary response to TRH and LHRH test in patients with polycystic ovary syndrome.

Micić D, Popović V, Minić S, Sumarac M, Kendereski A, Damjanović S, Manojlović D, Mićić J

Endocrinologia experimentalis1 Mar 1990

PMID2113856 (opens in a new tab)PepBankPUB-02113856
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Gonadorelin (GnRH, LHRH).

  1. 01HumanNot a test of Gonadorelin (GnRH, LHRH) aloneNon-randomized trialOther

    In 8 women with polycystic ovary syndrome, the LH response to a combined LHRH and TRH test did not differ before and after naloxone.

    In plain wordsIn women with polycystic ovary syndrome, naloxone did not change the LH response to a combined LHRH and TRH test. LHRH was a test tool.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    No significant changeLH response to LHRH test after naloxone
    Study

    n = 8

    Comparator
    Before naloxone
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    No significant difference was found in the hormone responses before and after naloxone injection.
    1 context sentence
    Summary · context
    The response of TSH, PRL, LH and FSH to combined test with LHRH (Relefact LH-RH, HOECHST; 0.1 mg) and TRH (Relefact TRH, HOECHST; 0.2 mg) was examined before (day I) and after naloxone (Narcanti, DUPONT) bolus of 0.8 mg (day III) in 8 patients with polycystic ovary syndrome

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

  2. 02HumanNot a test of Gonadorelin (GnRH, LHRH) aloneNon-randomized trialOther

    In 8 women with polycystic ovary syndrome, the FSH response to a combined LHRH and TRH test did not differ before and after naloxone.

    In plain wordsIn women with polycystic ovary syndrome, naloxone did not change the FSH response to a combined LHRH and TRH test. LHRH was a test tool.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    No significant changeFSH response to LHRH test after naloxone
    Study

    n = 8

    Comparator
    Before naloxone
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    No significant difference was found in the hormone responses before and after naloxone injection.
    1 context sentence
    Summary · context
    The response of TSH, PRL, LH and FSH to combined test with LHRH (Relefact LH-RH, HOECHST; 0.1 mg) and TRH (Relefact TRH, HOECHST; 0.2 mg) was examined before (day I) and after naloxone (Narcanti, DUPONT) bolus of 0.8 mg (day III) in 8 patients with polycystic ovary syndrome

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.